AB Science receives US FDA & EMA authorization for confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer: Paris Monday, July 7, 2025, 11:00 Hrs ...

("LIXTE” or the "Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the ...

Objectives Elevated liver enzyme concentrations in blood are indicative of liver diseases and may provide an early signal for being at risk for other chronic diseases. Our study aimed to assess the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...